Document is current
Any future updates will be listed below
-
Authors
Wattanachayakul, Phuuwadith
Kittipibul, Veraprapas
Abraham, William T.
Hahn, Rebecca T.
Pinney, Sean P.
Desai, Akshay S.
Burkhoff, Daniel
Fudim, Marat
- License Information
-
More Information
Article History
Received: 11 August 2025
Accepted: 18 September 2025
First Online: 30 September 2025
Declarations
:
: Dr Fudim was supported by the NIH, Bodyport, Sardocor, and Doris Duke. He is a consultant/has ownership interesting in Abbott, Ajax, Alio Health, Alleviant, Analog, Andera, Artha, Audicor, AxonTherapies, Bayer, Bodyguide, Bodyport, Boston Scientific, Broadview, Cadence, Cardioflow, Coridea, CVRx, Daxor, Edwards LifeSciences, Echosens, EKO, Feldschuh Foundation, Fire1, FutureCardia, Galvani, Gradient, Hatteras, HemodynamiQ, Impulse Dynamics, Intershunt, Medtronic, Merck, NIMedical, NovoNordisk, NucleusRx, NXT Biomedical, Orchestra, Pharmacosmos, Presidio, Procyreon, Proton Intelligence, ReCor, Rockley, SCPharma, Shifamed, Splendo, STAT Health, Summacor, SyMap, Verily, Vironix, Viscardia, and Zoll. Dr Burkhoff has received speaker honorarium from Abiomed/Johnson and Johnson; receives institutional support from Ancora Heart; is a consultant to Corvia Medical, Impulse Dynamics, Orchestra Biomedical, and Zoll Medical Corp; and a minor shareholder in Aquapass, Orchestra Biomedical, and Xenter. Dr Hahn reports speaker fees from Abbott Structural, Baylis Medical, Edwards Lifesciences, and Philips Healthcare; she has institutional consulting contracts for which she receives no direct compensation with Abbott Structural, Anteris, Boston Scientific, Edwards Lifesciences, Medtronic, Novartis, and Philips Healthcare. Dr Pinney was supported by Abbott, ADI, Ancora, CareDx, Cordio, Medtronic, Nuwellis, Restore Medical, Transmedics, and Valgen Medtech. Dr Abraham reports consulting fees from Abbott, AquaPass, Cordio, CVRx, Innoventric, Relief Cardiovascular, Sensible Medical, Vectorious, WhiteSwell, and Zoll Respicardia; speaker honoraria from Impulse Dynamics; and holds leadership roles as a member of the Board of Directors at scPharmaceuticals and as Medical Director at JNJ V-Wave. Dr Desai has received research grants from Bayer, Abbott, Alnylam, AstraZeneca, and Novartis. He has also received consulting fees from Bayer, Abbott, Alnylam, AstraZeneca, Avidity Biopharma, Axon Therapeutics, Biofourmis, Boston Scientific, Endotronix, GlaxoSmithKline, Medpace, Medtronic, Merck, New Amsterdam, Novartis, Parexel, Regeneron, Roche, River2Renal, scPharmaceuticals, Veristat, Verily, and Zydus, all outside the submitted work. All other authors report no conflicts of interest.
